Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Ridgewood Investments LLC

Ridgewood Investments LLC reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 17.7% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 11,008 shares of the biopharmaceutical company’s stock after selling 2,364 shares during the quarter. Ridgewood Investments LLC’s holdings in Gilead Sciences were worth $1,017,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. nVerses Capital LLC acquired a new position in Gilead Sciences in the 3rd quarter valued at $25,000. Valued Wealth Advisors LLC boosted its position in shares of Gilead Sciences by 101.9% during the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 161 shares in the last quarter. Strategic Investment Solutions Inc. IL purchased a new position in shares of Gilead Sciences in the 2nd quarter valued at about $33,000. Cedar Wealth Management LLC increased its holdings in shares of Gilead Sciences by 51.6% in the 2nd quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 160 shares in the last quarter. Finally, Friedenthal Financial purchased a new position in shares of Gilead Sciences in the 3rd quarter valued at about $50,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 8,500 shares of the business’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $91.96, for a total transaction of $781,660.00. Following the transaction, the chief financial officer now directly owns 132,373 shares of the company’s stock, valued at approximately $12,173,021.08. The trade was a 6.03 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Jeffrey Bluestone sold 6,788 shares of the business’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total transaction of $620,355.32. Following the transaction, the director now directly owns 8,920 shares in the company, valued at approximately $815,198.80. The trade was a 43.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 453,734 shares of company stock worth $41,902,086. Company insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. Maxim Group downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating in a report on Friday, November 8th. Morgan Stanley upgraded shares of Gilead Sciences from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $87.00 to $113.00 in a report on Friday. The Goldman Sachs Group increased their price target on shares of Gilead Sciences from $74.00 to $84.00 and gave the company a “neutral” rating in a report on Thursday, November 7th. Leerink Partners upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and increased their price target for the company from $74.00 to $96.00 in a report on Monday, October 21st. Finally, Royal Bank of Canada reissued a “sector perform” rating and issued a $84.00 price objective on shares of Gilead Sciences in a research note on Wednesday, December 11th. Eleven research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $97.96.

Gilead Sciences Trading Down 0.0 %

Shares of GILD stock traded down $0.03 during trading hours on Friday, hitting $89.11. 2,827,181 shares of the company were exchanged, compared to its average volume of 5,183,874. The firm has a market cap of $111.05 billion, a PE ratio of 990.11, a PEG ratio of 2.24 and a beta of 0.18. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $98.90. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. The firm has a fifty day moving average of $91.93 and a 200 day moving average of $83.06.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating the consensus estimate of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The firm had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. During the same quarter last year, the firm posted $2.29 earnings per share. Gilead Sciences’s revenue for the quarter was up 7.0% compared to the same quarter last year. Analysts expect that Gilead Sciences, Inc. will post 4.36 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, December 30th. Investors of record on Friday, December 13th were issued a $0.77 dividend. The ex-dividend date of this dividend was Friday, December 13th. This represents a $3.08 annualized dividend and a yield of 3.46%. Gilead Sciences’s payout ratio is 3,422.22%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.